Laurie Freire Boullosa

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Venues

Pharmaceutics

Oncoimmunology

Antioxidants (Basel, Switzerland)

Cancer immunology, immunotherapy : CII

Centre for Oncological Research

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centre for Oncological Research Oct 01 2017 - Oct 01 2022

Belgium

PhD student

Publications

Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Céline Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H De Vos, Filip Lardon, Evelien L J Smits, Christophe Deben
Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Antioxidants (Basel, Switzerland) 12 (3) (2023)
Tal Flieswasser, Astrid Van den Eynde, Laurie Freire Boullosa, Jöran Melis, Christophe Hermans, Céline Merlin, Ho Wa Lau, Jonas R M Van Audenaerde, Filip Lardon, Evelien L J Smits, Patrick Pauwels, Julie Jacobs
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer. Oncoimmunology 12 (1) (2023)
Tal Flieswasser, Astrid Van den Eynde, Laurie Freire Boullosa, Jöran Melis, Christophe Hermans, Céline Merlin, Ho Wa Lau, Jonas R M Van Audenaerde, Filip Lardon, Evelien L J Smits, Patrick Pauwels, Julie Jacobs
Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer. Oncoimmunology 12 (1) (2023)
Laurie Freire Boullosa, Jinthe Van Loenhout, Tal Flieswasser, Christophe Hermans, Céline Merlin, Ho Wa Lau, Elly Marcq, Marlies Verschuuren, Winnok H De Vos, Filip Lardon, Evelien L J Smits, Christophe Deben
Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Antioxidants (Basel, Switzerland) 12 (3) (2023)
Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R Y De Meyer, Filip Lardon, Evelien L J Smits, Christophe Deben
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics 14 (12) (2022)
Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R Y De Meyer, Filip Lardon, Evelien L J Smits, Christophe Deben
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics 14 (12) (2022)
Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R Y De Meyer, Filip Lardon, Evelien L J Smits, Christophe Deben
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics 14 (12) (2022)
Laurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, Ho Wa Lau, Céline Merlin, Elly Marcq, Farnaz Sedigheh Takhsha, Wim Martinet, Guido R Y De Meyer, Filip Lardon, Evelien L J Smits, Christophe Deben
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model. Pharmaceutics 14 (12) (2022)
Stephanie Jordaens, Leah Cooksey, Laurie Freire Boullosa, Viggo F I Van Tendeloo, Evelien L J Smits, Kenneth Ian Mills, Kim H Orchard, Barbara-Ann Guinn
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer immunology, immunotherapy : CII 69 (5) (2020)

Laurie Freire Boullosa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Laurie Freire Boullosa